Competition and Innovation: The Breakup of IG Farben
By Felix Poege
IG Farben used to be the world’s largest chemical company and a major innovator – until it was broken up in one of the largest antitrust events in history.
Category: Research
It Was 50 Years Ago Today: Recording Copyright Term and the Supply of Music
By Jeremy Watson , Megan MacGarvie, and John McKeon
Technological change has led to a rapid and dramatic evolution of business models in copyright-intensive industries, especially in the music industry.
Computers as Stepping Stones? Technological Change and Equality of Labor Market Opportunities
By Melanie Arntz, Cäcilia Lipowski, Guido Neidhöfer and Ulrich Zierahn-Weilage
The effect of social background on professional success decreases when technological change is strong.
Patent thickets, stock returns, and conditional CAPM
By Po-Hsuan Hsu, Hsiao-Hui Lee, and Tong Zhou
In order to accelerate knowledge accumulation and technical progress, governments introduced patent systems to encourage inventors to share their ideas, discoveries, and inventions with the public.
Profit Taxation, R&D Spending, and Innovation
By Andreas Lichter, Max Löffler, Ingo E. Isphording, Thu-Van Nguyen, Felix Poege, Sebastian Siegloch
Advances in pharmaceuticals and vaccines, robotics and artificial intelligence dominate newspaper headlines.
Do Incentives Matter for Hospitals?
By Tal Gross, Adam Sacarny, Maggie Shi & David Silver
America spends about 6 cents of every dollar at its hospitals. A natural question to ask: why not just pay those hospitals less?
How important is price variation between health insurers?
By Stuart V. Craig, Keith Marzilli Ericson, and Amanda Starc
We examined how prices vary between insurers for the same procedure at the same hospital, using a dataset of all commercial Massachusetts hospital claims.
The role of TRIPS in encouraging pharmaceutical technological diffusion in developing countries
Iain Cockburn, Tim Wilsdon, Michele Pistollato, Rajini Jayasuriya, and Thomas Watson
The 1995 TRIPS Agreement between member states of the World Trade Organization (WTO) defines minimum standards of intellectual property (IP) protection and enforcement.
US Insurer Spending on Ivermectin Prescriptions for COVID-19
Insurers heavily subsidize the cost of ivermectin prescriptions for COVID, despite the lack of evidence that ivermectin is effective for COVID. In a new paper, published in JAMA, Questrom professor and TPRI co-lead Rena Conti with colleagues Kao-Ping Chua and Nora Becker (both University of Michigan) estimate that U.S. insurers may have wasted $2.5 million on these drugs in the week of August 13, 2021 alone.
Addressing the trade-off between lower drug prices and incentives for pharmaceutical innovation
TPRI faculty co-lead and Questrom faculty Rena Conti will testify at the upcoming U.S. House of Representatives hearing of the Committee on Oversight and Reform, entitled “Unsustainable Drug Prices: Findings from the Committee’s Drug Pricing Investigation and the Need for Structural Reforms.” on Friday, December 10, 2021, at 10 a.m. Professor Conti will discuss recently published papers germane to the current public debate on lowering prescription drug prices.